Forward Pharma Reports Fourth Quarter and Year End 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Forward Pharma Reports Fourth Quarter and Year End 2015 Financial and Operational Results

COPENHAGEN, Denmark, April 12, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (“We” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2015. Net loss for the fourth quarter and year ended December 31, 2015 was $9.6 million and $37.0 million, respectively. Loss per share for the fourth quarter and year ended December 31, 2015 was $0.20 and $0.79, respectively.  On a non-GAAP basis, after removing the effect of non-cash income and expense items, our fourth quarter and year ended 2015 net loss would have been $8.4 million and $35.4 million, or $0.18 and $0.76 per share, respectively. As of December 31, 2015, the Company had $176.7 million in cash, cash equivalents and marketable securities, with no debt outstanding. 

“We continue to advance our clinical and intellectual property objectives including strengthening our clinical development team,” said Peder Andersen, Chief Executive Officer of Forward.

Fourth Quarter ended December 31, 2015 Financial and Operational Results

The net loss for the fourth quarter of 2015 was $9.6 million compared to a net loss of $2.0 million for the fourth quarter of 2014, excluding the preferential distribution to Class B shareholders.  

Research and development expenses were $8.6 million for the quarter ended December 31, 2015 compared to $3.9 million for the fourth quarter of 2014. This increase was due primarily to a $4.2 million increase in clinical and pre-clinical expenses as we expanded our development activities to include several pre-clinical studies and Phase 1 trials as well as preparations for our planned Phase 3 trial of FP187 in relapsing-remitting multiple sclerosis (RRMS). Share-based compensation also increased by $1.0 million in connection with equity awards granted during the year. We continue to anticipate that our spending for research and development will increase in future quarters as we advance our clinical programs and patent prosecution, including our patent interference proceeding. 

General and administrative expenses were $3.6 million for the quarter ended December 31, 2015 compared to $4.0 million for the fourth quarter of 2014. The decrease in general and administrative expenses in the fourth quarter 2015 versus the prior year was primarily due to a decrease in costs related to our initial public offering that was completed in 2014, partially offset by an increase in share-based compensation expense, legal fees and costs associated with being a public company. We expect our rate of general and administrative spending will increase in the future as we expand our business and advance our intellectual property portfolio including expenditures in connection with the lawsuits against Biogen in Europe.

Non-cash stock based compensation expense included in total operating expenses was $3.5 million for the fourth quarter of 2015 versus $2.5 million for the same period in 2014.

As of December 31, 2015, the Company had $176.7 million in cash, cash equivalents and marketable securities.

IP Update

We continue to advance our intellectual property portfolio. The following summarizes the current status of and recent developments concerning several of our most important U.S. and European patents and patent applications:

  • U.S. IP: Interference schedule accelerated with oral arguments scheduled for November 2016.   On August 19, 2015, the USPTO re-declared the interference between Forward and a subsidiary of Biogen, Inc. regarding claims to the treatment of multiple sclerosis, or MS, with a 480 mg daily dose of DMF (dimethyl fumarate), the active ingredient in Tecfidera ® . The USPTO confirmed Forward as the senior party based on having an earlier benefit date of our U.S. Patent Application No. 11/576,871. Biogen was deemed the junior party with respect to its U.S. Patent No. 8,399,514. In August 2015, the parties filed priority statements and motions related to validity and benefit. Oppositions to motions are due June 1, 2016 and the oral argument is now scheduled for November 30, 2016 (previously January 2017).   
  • European IP: Hearing in Germany postponed under an agreement with Biogen.   On November 18, 2014, we filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Düsseldorf, Germany, asserting infringement of our utility model by Biogen’s marketing of Tecfidera ® in Germany with a label instructing a daily dose of 480 mg for the treatment of MS. On May 22, 2015, we expanded the existing lawsuit to include the assertion of infringement of our European patent EP2801355. The ’355 patent covers, among other things, the treatment of MS with 480 mg per day of DMF using pH‑controlled compositions, which have an enteric coating. We seek damages for Biogen’s sales of Tecfidera ® in Germany. If the court agrees with our assertion, we expect the court will declare that we would be entitled to damages and/or compensation for unjust enrichment. An oral hearing in Germany originally scheduled for March 24, 2016 at the Regional Court in Düsseldorf has been stayed (i.e. postponed) under a mutual agreement between the two parties. That stay will expire, in the case of the ’355 patent, upon an initial decision in the European Patent Office (EPO) opposition proceedings against the ’355 patent, and in the case of the utility model, upon a decision in both the ’355 EPO opposition proceedings and the utility model cancellation proceedings. 

Clinical Update

Our development plan for our lead drug, FP187, is focused on the RRMS indication. In consultation with a clinical research organization, we are continuing to prepare for a single beta interferon-controlled Phase 3 trial in RRMS. In parallel, we are evaluating alternative Phase 3 clinical strategies in RRMS, which could shorten our time to commercialization and/or reduce costs. We expect to complete these evaluations during 2016, in anticipation of beginning the Phase 3 trial in the second half of 2016. 

We are currently performing additional Phase 1 studies on FP187 to evaluate its in vivo release profile as well as tolerability. In addition, we are planning to conduct a human mass‑balance/metabolic profile study, which is a requirement of regulatory agencies.

Our nonclinical development plan for our lead drug, FP187, is designed to support regulatory submissions with a full toxicology study package.

Corporate Update

Forward Pharma also announced today that Rupert Sandbrink, M.D., Ph.D. joined the Company on March 1, 2016 as Executive Vice President, Multiple Sclerosis/Neurology and Immunology. Dr. Sandbrink has more than 17 years of expertise in the pharmaceutical industry in all stages of clinical development, including product launch and medical affairs. Prior to joining Forward Pharma, Dr. Sandbrink was Vice President and Therapeutic Area Head in Medical and Clinical Development and Clinical Sciences at Schering AG and later Bayer AG, with a focus on MS, other neurologic diseases and auto-immune disorders.

                   
  Forward Pharma A/S  
  Condensed Consolidated Statement of Operations  
  (in thousands, except per share amounts)  
                   
      Year Ended     Three Months Ended    
      December 31st       December 31st    
      2015       2014       2015       2014    
                   
  Research and development $   (33,727 )   $   (10,547 )   $   (8,623 )   $   (3,931 )  
  General and administrative     (15,852 )       (9,154 )       (3,592 )       (3,998 )  
  Total operating expenses     (49,579 )       (19,701 )       (12,215 )       (7,929 )  
                   
  Foreign exchange gain     11,933         5,589         2,328         5,748    
  Other     306         (5,154 )       (30 )       72    
  Net (loss) before taxes     (37,340 )       (19,266 )       (9,917 )       (2,109 )  
                   
  Income tax benefit     336         250         336         138    
  Net (loss)       (37,004 )       (19,016 )       (9,581 )       (1,971 )  
                   
  Preferential distribution     -         (42,734 )       -         (42,734 )  
  Net (loss)   $     (37,004 )   $     (61,750 )   $     (9,581 )   $     (44,705 )  
                   
  Net (loss) per ordinary share                
  Basic and diluted $     (0.79 )   $     (1.79 )   $     (0.20 )   $     (1.01 )  
                   
  Weighted-average shares used basic and diluted       46,749         34,490         46,872         44,094    
                   
                   
  Forward Pharma A/S  
  Reconciliation of net (loss) as reported to non-GAAP net (loss)  
  (in thousands, except per share amounts)  
                   
      Year Ended     Three Months Ended    
      December 31st       December 31st    
      2015       2014       2015       2014    
                   
  Net (loss) as reported  $   (37,004 )   $   (61,750 )   $   (9,581 )   $   (44,705 )  
  Adjustments for non-cash items:                
  Preferential distribution     -         42,734         -         42,734    
  Share-based compensation     13,541         5,951         3,506         2,477    
  Foreign exchange gain     (11,933 )       (5,589 )       (2,328 )       (5,748 )  
  Fair value adjustment to convertible notes     -         3,823         -         (20 )  
  Fair value adjustment shareholder warrants     -         968         -         (82 )  
                   
  Non-GAAP net (loss) $     (35,396 )   $     (13,863 )   $     (8,403 )   $     (5,344 )  
                   
  Non-GAAP net (loss) per share information:                
  Weighted-average shares used     46,749         34,490         46,872         44,094    
  Non-GAAP basic and diluted per share (net) loss   $     (0.76 )   $     (0.40 )   $     (0.18 )   $     (0.12 )  
                   

This press release uses a non-GAAP measure of net loss that is a financial measure that is not calculated in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The Company believes that the presentation of non-GAAP net loss is useful to investors because it excludes non-cash items that do not affect the Company’s liquidity and period to period changes, most of which are not within the control of the Company. Non-cash items include: (i) preferential distribution to Class B shareholders; (ii) share-based compensation expense; (iii) non-cash foreign exchange gains or (losses) and (iv) fair value adjustments of convertible notes and shareholder warrants. However, there are limitations in the use of non-GAAP financial measures as they exclude certain income and expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measure may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented herein should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with IFRS.

           
  Forward Pharma A/S
  Condensed Consolidated Balance Sheets
  (in thousands)
           
      December 31st       December 31st    
      2015       2014    
  Assets        
  Cash, cash equivalents and available-for-sale financial assets   $   176,652     $   223,484    
  Other assets     6,252         1,825    
  Total assets $     182,904     $     225,309    
           
  Equity and Liabilities        
  Shareholders' equity $   176,693     $   222,394    
  Liabilities     6,211         2,915    
  Total equity and liabilities $     182,904     $     225,309    
           

Relevant Intellectual Property Sources: 

USPTO Interference with Biogen: The motions are publicly available on the USPTO interference website at  https://acts.uspto.gov/ifiling/PublicView.jsp , using interference number 106023.

Forward Pharma U.S. and European patent and patent applications can be found by using the following links:  USPTO: http://www.uspto.gov/   USPTO Public Pair: http://portal.uspto.gov/pair/PublicPair   EPO: https://register.epo.org/regviewer  

About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. Since our founding in 2005, we have worked to advance unique formulations of DMF, which is an immune modulator, as a therapeutic agent to improve the health and well-being of patients with immune disorders including multiple sclerosis.  FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose.

Our principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on NASDAQ Stock Market ( FWP ). For more information about the Company’s products and developments, please visit our web site at http://www.forward-pharma.com . 

Forward Pharma A/S Media Contact: Sharon Klahre, Director, Investor Relations Forward Pharma USA, LLC 7 Skyline Drive Hawthorne, NY 10532 SK@forward-pharma.com   +1 914-752-3542

The Ruth Group Lee Roth lroth@theruthgroup.com   +1 646-536-7014

Forward Looking Statements: Certain statements in this press release may constitute “forward-looking statements” of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as “believe,” “expect,” “anticipate,” “hope,” “would” and “potential.” Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company’s ability to obtain, maintain and defend issued patents with protective claims; the issuance and term of patents; the Company’s ability to prevail in or obtain a favorable decision in any patent interference or infringement action; the Company’s ability to recover damages in any patent infringement action; uncertainties relating to our development plans and activities, including the commencement of any clinical trial and the results, timing, cost and location thereof; risks and uncertainties related to the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties; our ability to commercialize and generate revenue from our sole clinical candidate, FP187; clinical development, and clinical trials of FP187 may not be successful; completion of required clinical trials may take longer than we anticipate, which could result in increased costs, limit our access to funding and delay or limit our ability to obtain regulatory approval for FP187. These and other factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2015.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Aircraft Rescue and Firefighting Vehicles Market Growth

Updated Category News Views 218

Overview of the Global Aircraft Rescue and Firefighting Vehicles Market The Global Aircraft Rescue and Firefighting Vehicles Market is on track for substantial growth, with projections indicating an increase from USD 51.2 billion in 2023 to USD 79.9 billion by 2033. This growth equates to a Compound Annual Growth Rate (CAGR) of 4.55% during the forecast period. The rise...

Continue Reading
Shifting Driver Attitudes: Rudeness on the Rise in PNW

Updated Category News Views 314

Driving Rudeness in the Pacific Northwest: A Growing Concern In recent times, there has been a noticeable increase in rudeness among drivers on the roads of the Pacific Northwest. A poll by PEMCO indicates that many residents in the region feel this shift in behavior is very real. Many drivers, approximately 73%, believe that traffic violations are on the rise, with...

Continue Reading
Beeline Transforming Mortgage Services with AI Agent Bob

Updated Category News Views 175

Beeline Holdings Makes AI Move with Agent Bob Beeline Holdings, known for its innovative approach in the mortgage industry, has embarked on an exciting transformation with its proprietary AI agent, Bob. Initially developed for customer support, Bob is venturing into direct sales and origination activities, marking a pivotal shift in how the company operates. Leading the...

Continue Reading
Simplilearn Unveils Alby AI to Redefine Upskilling

Updated Category News Views 27

An Era of Tailored Education Kicks Off How many times have we heard about some 'revolutionary' AI hitting industries like a bull in a china shop, only to fizzle out when reality sets in? Well, hang on to your hats because Simplilearn's latest move is cooking up something genuinely spicy in the education sector. They've just launched Alby AI, claimed to be the world's...

Continue Reading
Faraday Future Launches Faraday X Brand with New EV Models

Updated Category News Views 188

Faraday Future Unveils Faraday X Brand and Innovative Electric Vehicles Faraday Future Intelligent Electric Inc. (Nasdaq: FFIE) has recently embarked on a thrilling new journey by launching its second brand, Faraday X (FX). This move is part of a strategic plan to create a comprehensive intelligent electric mobility ecosystem. With the introduction of FX, Faraday Future...

Continue Reading